Eli Lilly Says Lebrikizumab Monthly Maintenance Dosing At Two Years Demonstrated Efficacy For Patients With Eczema
Portfolio Pulse from Shivani Kumaresan
Eli Lilly has announced that patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance. The results from the ADjoin long-term extension study will be presented at the 43rd Annual Fall Clinical Dermatology Conference from October 19-22. Despite the positive news, LLY shares are trading lower by 1.47% at $582.10.
October 20, 2023 | 3:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's lebrikizumab has shown sustained efficacy in a long-term study for atopic dermatitis. Despite this, the company's shares are trading lower.
The positive results from the long-term study of lebrikizumab indicate a potential new revenue stream for Eli Lilly. However, the stock price has fallen, possibly due to market factors unrelated to this news. The impact of this news on the stock price may become more apparent in the coming days.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100